PetMed Express Q1 2027 Earnings Report

PetMed Express EPS Results

• Actual EPS: -$0.28
• Consensus EPS: $0.12
• Beat/Miss: Missed by -$0.40
• One Year Ago EPS: N/A

PetMed Express Revenue Results

• Actual Revenue: $41.02 million
• Expected Revenue: $71.00 million
• Beat/Miss: Missed by -$29.99 million
• YoY Revenue Growth: N/A

PetMed Express Announcement Details

• Quarter: Q1 2027
• Date: 8/13/2026
• Time: After Market Closes
• Conference Call Date: Thursday, August 13, 2026
• Conference Call Time: 4:30PM ET

PetMed Express (NASDAQ:PETS) operates as an online and catalog-based pet pharmacy and retail supplier under the 1-800-PetMeds brand name. The company distributes prescription and non‐prescription medications, nutritional supplements, flea and tick control products, and a range of pet health supplies directly to consumers. Through its licensed veterinary pharmacy in Delray Beach, Florida, PetMed Express fills orders for dogs, cats and other companion animals, offering both branded and generic products alongside its own private‐label formulations.

Founded in 1996 by Marc Puleo, PetMed Express built its business on the premise of convenience and cost savings for pet owners seeking reliable access to veterinary medications. The company launched its initial public offering in 2000 and has since developed an in‐house team of veterinarians and pharmacy professionals to review prescriptions and provide customer support. With a multi‐channel approach that includes online ordering, telephone service and direct mail catalogs, PetMed Express seeks to simplify the process of obtaining essential pet health products.

PetMed Express primarily serves customers across the United States, with select offerings available in Canada. Its operations center around a fulfillment facility in Florida, supported by a network of third‐party carriers for nationwide delivery. The company is led by its founder and Chief Executive Officer, Marc Puleo, who oversees strategy and business development alongside a management team experienced in pharmaceutical distribution and e-commerce. PetMed Express continues to focus on expanding its product portfolio, enhancing digital capabilities and maintaining compliance with regulatory standards in veterinary pharmacy.

PetMed Express Q1 2027 Earnings Call Transcript

Key Takeaways

• Negative Sentiment: Revenue remained weak: Q1 net sales fell 19.9% year over year to $41.0 million, primarily due to continued softness in prescription medication sales, while gross margin declined to 27.6% from 28.1%.
• Neutral Sentiment: The net loss narrowed substantially to $6.1 million from $34.2 million a year ago, largely because the prior-year period included a goodwill and trade-name impairment charge; however, adjusted EBITDA loss worsened to $3.4 million from $2.7 million.
• Positive Sentiment: Customer acquisition efficiency improved, with approximately 70,000 new customers added and customer acquisition cost declining 15% year over year to $60. Recurring sales increased to 61.5% of gross sales from 57.6%, supporting the company’s subscription-driven base.
• Positive Sentiment: PetMeds launched its first large-scale white-label pharmacy partnership with Rural King, giving customers across more than 150 stores access to pet medications and auto-ship services while creating a potential new customer acquisition and B2B revenue channel.
• Positive Sentiment: The company agreed to sell and lease back its headquarters and distribution center for $37 million, which management expects will strengthen the balance sheet and provide financial flexibility; PetMeds had $13.1 million in cash and no debt at quarter-end.

Presentation

[Operator]

Greetings, and welcome to the PetMed Express Inc. Q1 2027 earnings results conference call. At this time, all participants are in a listen-only mode. It is now my pleasure to introduce your host, Reed Anderson with ICR. You may begin.

[Reed Anderson, Managing Director at ICR]

Thank you, and welcome to the PetMed Express fiscal first quarter 2027 earnings conference call. With us on the call today are Leslie Campbell, PetMeds Chairman and Interim CEO and President, and Doug Krulik, Interim Principal Financial Officer and Chief Accounting Officer. Certain information included during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Securities Exchange Act of 1934, as amended, that may involve a number of risks and uncertainties. These statements are based on our beliefs as well as assumptions we've used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties, and assumptions. Actual results could differ materially from those projected. There can be no assurance that any forward-looking results will occur or be realized.

[Reed Anderson, Managing Director at ICR]

Nothing contained in this presentation is or should be relied upon as a representation or warranty as to any future matter, including any matter in respect of the operations or business or financial condition of PetMeds. PetMeds undertakes no obligation to update publicly these forward-looking statements based on subsequent events, except as may be required by applicable law, regulation, or other competent legal authority. We have identified various risk factors associated with our operations in our most recent annual report on Form 10-K and other filings with the Securities and Exchange Commission. Now, let me turn the call over to Leslie Campbell, PetMeds Chairman and Interim CEO and President.

[Leslie Campbell, Chairman, Interim CEO, and President at PetMed Express]

Thank you, Reed, and welcome to everyone joining our call this afternoon. Following my opening remarks, Doug will provide a detailed overview of our financial results. In this first quarter, we continued to build on the operational and financial foundation we began transforming last year with a significant focus on enhancing shareholder value, optimizing our capital allocation, streamlining our cost structure, developing new revenue streams, improving our customer retention while efficiently gaining access to new customers, modernizing our technology infrastructure, enhancing our customer service capabilities, and speeding up deliveries to our customers. While the direct-to-consumer pet health landscape remains intensely competitive, our focus is single-minded: driving long-term shareholder value and establishing a direct, clear path back to sustainable profitability. To that end, our board continues to evaluate all capital allocation and strategic priorities with complete discipline.

[Leslie Campbell, Chairman, Interim CEO, and President at PetMed Express]

While we believe we are implementing the strategy and taking the actions necessary to enhance shareholder value, our board and management team remain open to considering any opportunities that have the potential to enhance value for all PetMed's shareholders. With respect to revenue growth and customer acquisition initiatives, we are diversifying our customer acquisition funnel beyond relying on traditional advertising and media channels, which continue to become more expensive. For example, key strategic initiatives, such as our first white label pharmacy offering, are reaching in-store shoppers and bringing them online. Leveraging the technology and infrastructure work we completed during Q4 and into the current quarter, we believe we're beginning to see the benefits of these investments show up in our day-to-day operations. Our new call center platform, launched in June, has helped us handle customer inquiries and sales more efficiently.

[Leslie Campbell, Chairman, Interim CEO, and President at PetMed Express]

Our new fraud prevention system, launched in Q4, continues to protect the business as order volumes evolve. During Q1, we completed a comprehensive process to upgrade our enterprise resource planning system, our ERP system, and in May, we successfully rolled out SAP as our ERP system enterprise-wide, further modernizing and strengthening our financial systems and reporting processes and representing the completion of one of the largest elements of our technology transformation initiative as we continue to replace legacy platforms. We also recently entered into a new freight agreement that both mitigates proposed cost increases from a previous carrier and provides faster and more trackable service, especially to our West Coast customers, who may now receive their orders up to two days faster. We believe that speeding up deliveries to our customers will significantly enhance their customer experience and customer satisfaction and lead to higher customer retention rates.

[Leslie Campbell, Chairman, Interim CEO, and President at PetMed Express]

All these ongoing technology and operational initiatives are creating a stronger foundation for a more scalable, efficient organization going forward. Before we move on to the first quarter results, I'd like to update you on two current topics. First, in a press release that we issued on June 30, we acknowledged receipt of an unsolicited, non-binding, and conditional proposal from SilverCape Investments to acquire all the outstanding shares of the company's stock for $3 per share in cash. Based on communications to date with SilverCape, the board has not yet reached any determination regarding SilverCape's proposal, and there is no assurance that any transaction will result. As stated in our June 30, 2026, press release, the company does not intend to comment further unless and until it determines that additional disclosure is appropriate or required.

[Leslie Campbell, Chairman, Interim CEO, and President at PetMed Express]

Secondly, regarding the search for a permanent CEO, the board is continuing this search with the assistance of a global executive search firm. Recruiting for this role a person firmly committed to driving long-term shareholder value and establishing a direct, clear path back to sustainable profitability remains a high priority for our board. Turning now to first quarter results. In Q1, we're pleased to see that sales have stabilized sequentially over the past several quarters. Although the year-over-year decline of 19.9% in first quarter net sales reflects continued softness in prescription medication sales. Our net loss for the first quarter narrowed significantly to $6.1 million, compared to a net loss of $34.2 million in the same period last year, reflecting our disciplined focus on managing operating costs, as well as the absence of a non-cash goodwill impairment charge.

[Leslie Campbell, Chairman, Interim CEO, and President at PetMed Express]

General and administrative expenses declined nearly 14% year-over-year, reflecting lower professional fees, and advertising expenses declined 30%, reflecting lower gross media spend and the selective elimination of several unproductive high-cost programs. At the same time, our recurring net sales, which include auto-ship and membership-related revenue, grew to 61.5% of total gross sales, up from 57.6% a year ago, underscoring the strength of our subscription-driven customer base. I also want to call out our continued improvement around customer acquisition. During the first quarter, we acquired approximately 70,000 new customers, and this metric has been trending upward over the past several quarters. In addition, we reduced our cost of acquiring a new customer by 15% in the first quarter to $60, compared to $71 in the same period last year.

[Leslie Campbell, Chairman, Interim CEO, and President at PetMed Express]

This meaningful improvement was driven by our ongoing advertising and media spend optimization, including the selective elimination of unproductive media spend and other strategic reductions in marketing costs. We see this improvement as an encouraging sign that our marketing investments are becoming more efficient, even as the broader advertising environment remains competitive. As we continue to focus on improving our customer acquisition and lowering our customer acquisition costs, I'm also pleased to share that in July, we officially launched our new co-branded online pharmacy offering with Rural King, giving Rural King's customers across more than 150 stores in 17 states convenient access to pet medications, prescription food, preventatives, and auto-ship services through a platform powered by PetMeds.

[Leslie Campbell, Chairman, Interim CEO, and President at PetMed Express]

This partnership, which we announced in April, represents our first large-scale white label pharmacy program, and we believe it is an important proof point for our strategy to efficiently grow our customer acquisition reach, including by converting in-store shoppers into online customers and developing new revenue streams by putting our pharmacy infrastructure, licensed pharmacists, e-commerce capabilities, and 30 years of expertise to work for our partners. In Rural King's case, particularly in the rural communities that they serve, where access to veterinary care and pet medications can be limited. We're proud of what this partnership represents in terms of future opportunities to efficiently gain access to new customers and develop new revenue streams, and we look forward to announcing the extension of our white label offering to additional partners in the near future.

[Leslie Campbell, Chairman, Interim CEO, and President at PetMed Express]

Turning to capital allocation, on July 23rd, we announced that we had entered into a definitive agreement for a sale-leaseback of our headquarters and distribution center buildings here in Delray Beach, Florida, for an aggregate purchase price of $37 million. Under the agreement, we will lease back the portion of the property housing our offices and Florida distribution center under a 10-year lease with subsequent renewal options, allowing us to continue operating out of the headquarters that has been home to PetMeds for the past decade. We expect this transaction to close within approximately 120 days from the date of the definitive agreement, subject to a due diligence period, negotiation of the definitive lease agreement, and other customary closing conditions.

[Leslie Campbell, Chairman, Interim CEO, and President at PetMed Express]

We see this transaction as a strategic next step in our ongoing commitment to sharpen our focus on our core pharmacy business, strengthen our balance sheet, and optimize our asset base by unlocking the value of our real estate, in turn, providing us with additional financial flexibility to continue investing in the initiatives with the greatest potential to drive shareholder returns. Looking ahead, the financial, operational, commercial, and cultural improvements we have implemented over the past 12 months, our strategic initiatives and partnerships, and our more disciplined approach to expense management and capital allocation have dramatically improved our foundation. They position us well for the future as we seek to drive long-term shareholder value and establish a direct, clear path back to sustainable profitability. We will continue to focus on operational excellence as a competitive pillar and core driver for sustainable long-term results and delivering value for shareholders.

[Leslie Campbell, Chairman, Interim CEO, and President at PetMed Express]

By leveraging our modernized technology and other operational initiatives, we can build on our exceptional service levels and improve customer retention. In addition, we continue leaning into our PetMeds pharmacy expertise and infrastructure to expand B2B relationships through membership programs and our white label fulfillment services to extend our reach to more customers. We remain deeply committed to our mission of ensuring pets live longer, healthier, and happier lives, and we are focused on delivering value for our shareholders through this disciplined execution of our strategic priorities. With that, I'll turn the call over to Doug Krulik for a more detailed review of our financial results for the first quarter.

[Doug Krulik, Interim Principal Financial Officer and Chief Accounting Officer at PetMed Express]

Thank you, Leslie. Net sales for the first quarter were $41 million compared to $51.2 million in the same period last year, representing a third consecutive quarter of revenue stabilization above $40 million, although a 19.9% year-over-year decline, primarily driven by decline in prescription medication sales, partially offset by lower consumer promotional usage. Gross profit was $11.3 million, compared to $14.4 million last year. As a percent of sales, gross profit this year was 27.6%, compared to 28.1% in the prior year, primarily reflecting lower manufacturer rebates as percentage of sales, partially offset by lower freight costs per order. General administrative expenses were $11.2 million, compared to $12.9 million last year, a 13.5% decrease. This year-over-year improvement was driven by lower professional fees, share-based compensation, and severance costs.

[Doug Krulik, Interim Principal Financial Officer and Chief Accounting Officer at PetMed Express]

Advertising expenses were $4.2 million, compared to $6 million last year, a decrease of 30.2%, reflecting lower gross media spend and the elimination of unproductive media. Depreciation and amortization was $2.1 million, compared to $2.3 million in the prior year period. Net loss for the first quarter was $6.1 million, or $0.28 per diluted share, compared to a net loss of $34.2 million or $1.65 per diluted share for the same period last year. This decrease in net loss was primarily driven by the absence of last year's goodwill and trade name impairment charge and, to a lesser extent, lower general and administrative and advertising expenses, partially offset by lower gross profit resulting from decreased net sales. Adjusted EBITDA loss was $3.4 million, compared to a loss of $2.7 million in the prior year period.

[Doug Krulik, Interim Principal Financial Officer and Chief Accounting Officer at PetMed Express]

Turning to our balance sheet, as of June 30, 2026, we had $13.1 million in cash and cash equivalents and no debt. With that, I'll turn the call back to Leslie for closing remarks.

[Leslie Campbell, Chairman, Interim CEO, and President at PetMed Express]

Thank you all for your time today and your interest in PetMeds. We are very grateful for the support of all of our shareholders and have appreciated the opportunity to communicate with many of you at different times throughout this quarter. I also want to thank our employees, as always, for how they bring their passion for our customers to life in their work every day. Finally, we always want to thank our loyal customers and their veterinarians who trust us to be part of helping pets live longer, healthier, happier lives. Thank you again for allowing us to share these first quarter results with you, and we look forward to updating you on our progress next quarter.

[Operator]

Ladies and gentlemen, thank you for your participation. This does conclude today's teleconference. Please disconnect your lines and have a wonderful day.

Participants

Executives

• Leslie Campbell, Chairman, Interim CEO, and President
• Doug Krulik, Interim Principal Financial Officer and Chief Accounting Officer

Analysts

• Reed Anderson, Managing Director at ICR